Moreover, since PKM2 activity is known to be modulated by various allosteric regulations in response to upstream glycolytic or purine nucleotide synthesis intermediates, acting on cancer cell metabolism might also affect the equilibrium between the high- and low-activity states of PKM2, making response prediction even more uncertain [13]. This evidence concerns the gene PKM and cancer.